Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
Frontiers | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
NIH study revises molecular classification for most common type of lymphoma | National Institutes of Health (NIH)
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. | Semantic Scholar
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
Diffuse Large B-Cell Lymphoma | NEJM
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma | Annals of Hematology
The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
Ibrutinib improves survival in young people with diffuse large B-cell lymphoma
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
JCI - Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma
Cancers | Free Full-Text | Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma: Trends in Cancer
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR
Frontiers | The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
